Our top pick for
Building a portfolio
Intercept Pharmaceuticals, Inc is a biotechnology business based in the US. Intercept Pharmaceuticals shares (ICPT) are listed on the NASDAQ and all prices are listed in US Dollars. Intercept Pharmaceuticals employs 498 staff and has a trailing 12-month revenue of around USD$312.7 million.
|52-week range||USD$18.15 - USD$95.98|
|50-day moving average||USD$22.468|
|200-day moving average||USD$30.2979|
|Wall St. target price||USD$41.64|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-10.436|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$312.7 million|
|Gross profit TTM||USD$307.4 million|
|Return on assets TTM||-20.28%|
|Return on equity TTM||-143254.91%|
|Market capitalisation||USD$685.7 million|
TTM: trailing 12 months
There are currently 7.5 million Intercept Pharmaceuticals shares held short by investors – that's known as Intercept Pharmaceuticals's "short interest". This figure is 3.7% up from 7.2 million last month.
There are a few different ways that this level of interest in shorting Intercept Pharmaceuticals shares can be evaluated.
Intercept Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Intercept Pharmaceuticals shares currently shorted divided by the average quantity of Intercept Pharmaceuticals shares traded daily (recently around 1.2 million). Intercept Pharmaceuticals's SIR currently stands at 6.49. In other words for every 100,000 Intercept Pharmaceuticals shares traded daily on the market, roughly 6490 shares are currently held short.
However Intercept Pharmaceuticals's short interest can also be evaluated against the total number of Intercept Pharmaceuticals shares, or, against the total number of tradable Intercept Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intercept Pharmaceuticals's short interest could be expressed as 0.23% of the outstanding shares (for every 100,000 Intercept Pharmaceuticals shares in existence, roughly 230 shares are currently held short) or 0.3604% of the tradable shares (for every 100,000 tradable Intercept Pharmaceuticals shares, roughly 360 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Intercept Pharmaceuticals.
Find out more about how you can short Intercept Pharmaceuticals stock.
We're not expecting Intercept Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Intercept Pharmaceuticals's shares have ranged in value from as little as $18.15 up to $95.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intercept Pharmaceuticals's is 1.5792. This would suggest that Intercept Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Intercept Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.